Home » Posts tagged with » Greg Behar
Nestlé to fully own Aimmune Therapeutics through $2bn deal

Nestlé to fully own Aimmune Therapeutics through $2bn deal

Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in the latter for about $2 billion. The deal is expected to help the Swiss conglomerate’s subsidiary Nestlé Health Science and Aimmune Therapeutics to create a global leader in the prevention […]

Nestlé to acquire majority stake in US collagen brand Vital Proteins

Nestlé Health Science (NHSc) has agreed to acquire a majority stake in Vital Proteins, a US collagen brand and a lifestyle and wellness platform that manufactures supplements, beverages, and food products. Financial terms of the deal were not disclosed. The closing of the transaction is subject to regulatory approval. Considered to be the most abundant […]

Continue reading …
Nestlé increases stake in Aimmune Therapeutics after Palforzia FDA approval

Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured an additional equity investment of $200 million from Nestlé Health Science. Based in California, Aimmune Therapeutics has been focused on the development and commercialization of treatments for potentially life-threatening food […]

Continue reading …
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle

Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma acquisition news. Financial details of the two deals have not been disclosed. The divestments are being taken up in an effort to wrap up the $63 billion AbbVie acquisition of […]

Continue reading …